Disc Medicine, Inc.
As of Oct 22, 2026, Disc Medicine is in Stage 3, the topping phase, now in week 4 (since Sep 25, 2026). It closed at $75.03, 20.3% below its 52-week high and above its 200-day average, which is falling.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IRON early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IRON among Biotechnology222nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …222 | IRON | Stage 3 · wk 4 | 45 | +13.5% |
Disc Medicine: quick answers
What stage is Disc Medicine in?
As of Oct 22, 2026, Disc Medicine (IRON) is in Stage 3, the topping phase. It entered Stage 3 on Sep 25, 2026 and is in week 4. What the four stages mean
Is Disc Medicine in an uptrend?
Its uptrend has stalled. Disc Medicine is in Stage 3, the topping phase that follows an advance. It trades 6.2% above its 200-day average, which is falling.
How far is Disc Medicine from its 52-week high?
Disc Medicine closed at $75.03 on Oct 22, 2026, 20.3% below its 52-week high of $94.11. Its 52-week low is $55.74.
How has Disc Medicine performed over the past year?
As of Oct 22, 2026, Disc Medicine is down 12.9% over the past year and down 5.1% so far in 2026.
Which sector and industry is Disc Medicine in?
Disc Medicine is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.